Skip to main content

Ethical Aspects of Genetic Screening in Israel

  • Michal Sagi (a1)
The Argument

Advances in genetic research make it possible to identify carriers of a growing number of genetic diseases. The World Health Organization (WHO) published several preconditions for community carrier screening. This paper aims to present some of the dilemmas about screening in Israel and the difficulties in following the WHO's helpful criteria.

Hide All
Abeliovich D., Quint A., Weinberg N., Verchezon G., Lerer I., Ekstein J., and Rubinstein E.. 1996. “Cystic Fibrosis Heterozygote Screening in the Orthodox Community of Ashkenazi Jews: The Dor Yesharim Approach and Heterozygote Frequency.” European Journal of Human Genetics 4:338–41.
Barton N. W., Furbish F. S, Murray G. I., Garfield M., and Brady R. O.. 1990. “Therapeutic Response to Intravenous Infusions of Glucocerebrosidase in a Patient with Gaucher Disease.” Proceedings of National Academy of Science USA 87:1913–16.
Beutler E. and Gelbart T.. 1996. “Glucocerebrosidase (Gaucher disease).” Human Mutation 8:207–13.
Broide E., Zeigler M., Ecksetin J., and Bach G.. 1993. “Screening for Carriers of Tay-Sachs Disease in the Ultraorthodox Ashkenazi Jewish Community in Israel.” American Journal of Medical Genetics 47:213–15.
Claus E. B., Tisch N., and Thompson W. D.. 1991. “Genetic Analysis of Breast Cancer in the Cancer and Steroid Hormone Study.” American Journal of Human Genetics 48:232–42.
Cohen T. 1998. Personal communication.
Croyle R. T., Achilles J. S., and Lerman C.. 1997. “Psychologic Aspects of Cancer Genetic Testing.” Cancer 80:569–75.
Easton D. 1997. “Breast Cancer Genes — What Are the Real Risks?Nature Genetics 16:210–11.
Gayther S. A., and Ponder B. A. J.. 1997. “Mutations of the BRC1 and BRC2 Genes and the Possibilities for Predictive Testing.” Molecular Medicine Today 3:168–74.
Goodman R. M. 1979. Genetic Dimensions Among the Jewish People. Baltimore: The Johns Hopkins University Press.
Grabowsky G. A. 1997. “Gaucher Disease: Gene Frequencies and Genotype/Phenotype Correlations.” Genetic Testing 1:512.
Kaback M. 1981. “Heterozygote Screening and Prenatal Diagnosis in Tay-Sachs Disease: A Worldwide Update.” In Lysosomes and Lysosomal Storage Diseases, edited by Callahan J. and Lowden J. A., 331–40. New York: Raven Press.
Kaufman M., Cohen J. Grinshpun, Karpati M., Peleg L., Goldman B., Akstein E., Adam A., and Navon R.. 1997. “Tay-Sachs Disease and HAXA Mutations among Moroccan Jews.” Human Mutation 10:295300.
Kerem E., Kalman Y. M., Yahav Y., Shoshani T., Abeliovich D., Szeinberg A., Rivlin J., Blau H., Tal A., Ben-Tur L., Springer C., Augarten A., Godfrey S., Lerer I., Branski D., Friedman M., and Kerem B.. 1995. “Highly Variable Incidence of Cystic Fibrosis and Different Mutation Distribution among Different Jewish Ethnic Groups in Israel.” Human Genetics 96:193–97.
Lerman C., Daly M., Sands C., Balshem A., Lustbader E., Heggan T., Goldstein L., James J., and Engstrom P.. 1993. “Mammography Adherence and Psychological Distress among Women at Risk for Breast Cancer.” Journal of National Cancer Institute 85:1074–80.
Miki Y., Swensen J., Slattuck-Gidens D., Futreal P. A., Harshman K., Tavtigian K., and Lui A.. 1994. “A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRC1.” Science 266:6671.
Modell B., and Kuliev A. M.. 1991. “Services for Thalassaemia as a Model for Cost Benefit Analysis of Genetic Services.” Journal of Inherited Metabolic Diseases 14:640–51.
National Academy of Science, National Research Council: Genetic Screening. 1975. Programs, Principles and Research. Washington, D.C.: NAS/NRC.
Newman B., Austim M. A., Lee M., and King M.-C.. 1988. “Inheritance of Human Breast Cancer: Evidence for Autosomal Dominant Transmission in High-Risk Families.” Proceedings of the National Academy of Science USA 85:3044–48.
Renhart G. 1997. Early Detection Program, Israeli Ministry of Health. Personal communication.
Roa B. B., Boyd A. A., Volcik K., and Richards C. S.. 1996. “Ashkenazi Jewish Population Frequencies for Common Mutations in BRC1 and BRC2.” Nature Genetics 14:185–87.
Sagi M. 1993. “Factors Influencing the Decision Whether to Have Prenatal Diagnosis in Families with Increased Risk for Genetic Disorders.” Ph.D. diss., The Hebrew University, Jerusalem.
Sagi M., Shiloh S., and Cohen T.. 1992. “Application of the Health Belief Model in a Study on Parents' Intentions to Utilize Prenatal Diagnosis of Cleft Lip and/or Palate.” American Journal of Medical Genetics 44:326–33.
Shiloh S. 1996. “Genetic Counseling: A Developing Area of Interest for Psychologists.” Professional Psychology: Research and Practice 27:475–86.
Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., and Tucker M. A.. 1997. “The Risk of Cancer Associated with Specific Mutations of BRCI and BRC2 among Ashkenazi Jews.” New England Journal of Medical Genetics 336:1401–08.
Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., and Micklem G.. 1995. “Identification of the Breast Susceptibility gene BRC2.” Nature 378:789–92.
Zimran A., Kay A., Gelbart T., Garver P., Thurston D., Saven A., and Beutler E.. 1992. “Gaucher Disease: Clinical, Laboratory, Radiologic and Genetic Features in 53 Patients.” Medicine 71:337–53.
Zlotogora J. 1997. Personal communication.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Science in Context
  • ISSN: 0269-8897
  • EISSN: 1474-0664
  • URL: /core/journals/science-in-context
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 11 *
Loading metrics...

Abstract views

Total abstract views: 199 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 20th January 2018. This data will be updated every 24 hours.